Which oral aminosalicylate for ulcerative colitis?

Drug and Therapeutics Bulletin

Volumn 49, Issue 1, 2011, Pages 8-12

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; EUDRAGIT; MESALAZINE; MESREN; OLSALAZINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANOREXIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE TITRATION; DRUG RELEASE; DRUG TREATMENT FAILURE; FATIGUE; FEVER; GASTROINTESTINAL DYSPLASIA; HEADACHE; HUMAN; INTESTINE; NAUSEA; PATIENT CARE; RASH; REMISSION; REVIEW; TENESMUS; THROMBOCYTOPENIA; TREATMENT INDICATION; ULCERATIVE COLITIS; UNITED KINGDOM; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 79952666138     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2011.01.0001     Document Type: Review

References (28)

1. Carter MJ et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl V): v1-v16..
2. Panaccione R, Sutherland LR. Clinical course and complications of ulcerative colitis and ulcerative proctitis. In: Targan SR et al (Eds). Inflammatory bowel disease: from bench to bedside. New York: Springer, 2005.
3. Farraye FA et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-74, 774.e1-4.
4. Joint Formulary Committee. British National Formulary. Edition 60. London: BMJ Group and RPS Publishing, September 2010.
5. Travis SPL et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62. (Pubitemid 351179488)
6. Pentasa slow release tablets 500mg. Summary of product characteristics, UK. Ferring Pharmaceuticals Ltd, September 2009.
7. Mezavant XL 1200mg, gastro-resistant, prolonged release tablets. Summary of product characteristics, UK. Shire Pharmaceutical Contracts Ltd, August 2010.
8. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 29-42. (Pubitemid 36140432)
9. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42. (Pubitemid 13051918)
10. Forbes A et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 1099-104.
11. Grosso A et al. A review of mesalazine MR formulations in ulcerative colitis. Brit J Clin Pharm 2009; 1: 333-6.
12. Dipentum capsules 250 mg, Dipentum tablets 500 mg. Summary of product characteristics, UK. UCB Pharma Ltd, March 2009.
13. Colazide 750mg capsules. Summary of product characteristics, UK. Laboratorios Almirall, S.A., August 2009.
14. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD000543. DOI: 10.1002/14651858.CD000543.pub2 [Last assessed as up-to-date: 12 February 2006]
15. Marakhouski Y et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 133-40.
16. Gibson PR et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1017-26.
17. Kruis W et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 707-15.
18. Rahimi R et al. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009; 54: 712-21.
19. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD000544. DOI: 10.1002/14651858.CD000544.pub2 [Last assessed as up-to-date: 12 February 2006]
20. Prantera C et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30: 908-18.
21. Velayos FS et al. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
22. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
23. Farup, PG et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 237-42.
24. R 24. Kruis W et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
25. Dignass AU et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 1009; 7: 762-9.
26. Sandborn WJ et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterol 2010; 138: 1286-96, 1296.e1281-3.
27. Clinical Knowledge Summaries. Ulcerative colitis - prescribing information: aminosalicylates [online]. Available: http://www.cks.nhs.uk/ ulcerative-colitis/prescribing-information/prescribing-information/ aminosalicylates[Accessed 17 December 2010].
28. Kornbluth A et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.